NCT06064344View on ClinicalTrials.gov

RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma

NANot yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 7, 2023

Primary Completion Date

October 6, 2027

Study Completion Date

October 6, 2027

Conditions
Primary Ocular Adnexal MALT Lymphoma
Interventions
DRUG

Rituximab

Intralesional Rituximab Injection

RADIATION

Involved Site Radiation Therapy

Involved Site Radiation Therapy

All Listed Sponsors
lead

Zhongshan Ophthalmic Center, Sun Yat-sen University

OTHER

NCT06064344 - RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma | Biotech Hunter | Biotech Hunter